Depression hastens nephropathy progression in type 1 diabetes: Study
Finland: Type 1 diabetes (T1D) patients having depression are at increased risk of diabetic nephropathy progression, a recent study has found. According to the study, published in the journal Diabetes Care, the purchase of antidepressants and diagnosed depression are associated with progression of nephropathy in T1D.
Aila J. Ahola, Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland, and colleagues investigated the relationship between depression and diabetic nephropathy progression in type 1 diabetes.
The study included data from 3,730 participants without end-stage renal disease (ESRD) at baseline. The patients were the participants of the Finnish Diabetic Nephropathy Study. Depression was assessed in three ways. Depression diagnoses were obtained from the Finnish Care Register for Health Care. Through the use of the, Drug Prescription Register, antidepressant agent purchase data were obtained. Depression symptoms were assessed using the Beck Depression Inventory (BDI). On the basis of urinary albumin excretion rate (AER), the participants were classified as those with normal AER, microalbuminuria, and macroalbuminuria. During the follow-up period, progression from normal AER to microalbuminuria, macroalbuminuria, or ESRD; from microalbuminuria to macroalbuminuria or ESRD; or from macroalbuminuria to ESRD was investigated.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.